Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Blue Cross Blue Shield of Louisiana (BCBS of LA) has joined the growing list of payors reducing the patient eligibility requirements for transcranial magnetic stimulation (TMS) treatment from four failed medication trials to two.

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

BrainsWay reported solid results in Q3 2023 and is now on the verge of sustainable profitability. BrainsWay's focus on larger organizations appears to be supporting growth and improving sales efficiency. While BrainsWay's share price has increased significantly from its lows, continued growth and consistent profitability are still not priced in.

BrainsWay: Positive Cash Flow And Continued Growth

Brainsway Ltd (NASDAQ:BWAY ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Jeffrey Cohen - Ladenburg Thalmann Carl Byrnes - Northland Capital Markets Boobalan Pachaiyappan - H.C. Wainwright Operator Good day and welcome to BrainsWay Third Quarter 2023 Earnings Call.

Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript

Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call to be Held Today at 8:30 AM EST BURLINGTON, Mass. and JERUSALEM, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression

Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems

BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie's Way Plus

BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.

The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.

BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS

Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan

BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region

Crocs

Luminar Technologies

While higher risk, identifying promising emerging disruptors early on can be very lucrative. For investors who identify such companies when their valuations seem reasonable, game-changing returns can be possible, once the market eventually recognizes their potential.

3 Stocks to Buy BEFORE They Become Wall Street Darlings

BrainsWay's Q2 results show continued revenue growth and improved cost control. The company is shifting its sales focus to larger institutions and enterprise customers, potentially improving sales efficiency. BrainsWay's market capitalization is still only approximately equal to its net cash position. Sustained profitability could move the stock significantly higher.

BrainsWay: Profitability Is Within Sight

Brainsway Ltd (NASDAQ:BWAY ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Jayson Bedford - Raymond James & Associates Steven Lichtman - Oppenheimer Boobalan Pachaiyappan - H.C. Wainwright & Co. Operator Good morning, ladies and gentlemen.

Brainsway Ltd (BWAY) Q2 2023 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2023 financial results and provided an operational update.

BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights

New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research

BrainsWay Announces Publication of Three New Deep TMS Research Publications

Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™ Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™

BrainsWay Accelerates International Expansion in India

30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network 30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network

BrainsWay Announces Significant Expansion in Western and Central U.S.

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities.

BrainsWay Announces Appointment of Ido Marom as CFO

BrainsWay Ltd. (NASDAQ:BWAY ) Q1 2023 Earnings Call May 17, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffery Cohen - Ladenburg Thalmann Glenn Shell - Raymond James Carl Byrnes - Northland Capital Markets Boobalan Pachaiyappan - H.C.

BrainsWay Ltd. (BWAY) Q1 2023 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2023 financial results and provided an operational update.

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives

BrainsWay Launches Investigator Initiated Study (IIS) Program

Brainsway Ltd. Sponsored ADR (BWAY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 17, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023

Real-World Evidence Demonstrates the Highest Response and  Remission Rates Observed to Date for Deep

BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression

BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.

BrainsWay Ltd. (BWAY) Q4 2022 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results and provided an operational update.

News for Brainsway Stock (BWAY)